Immediate and medium-term results of aortic valve replacement with biological prosthesis in elderly patients: experience of one center

Abstract

Objective. To analyze the immediate and medium-term results of prosthetics of the aortic valve (AV) using biological prosthesis in elderly patients.

Material and methods. The study included 198 patients with AV pathology [85 men (42.9 %)/113 women (57.1 %)]. The median age was 70 [66–73] years. There were 175 (88.4 %) patients with sclerodegenerative AV, 5 (2.5 %) – with infectious endocarditis and 30 patients (15.2 %) had bicuspid AV.

Results. The hospital mortality was 4.5 %. The causes of mortality were multiple organ failure syndrome, in 1 case – developed peritonitis. In 14 patients (7.1 %) there was a rhythm disturbance in the form of AF, in 9 (4.5 %) – a complete AV block, in connection with which a permanent pacemaker was implanted. Four patients (2 %) underwent resternotomy for bleeding. Two patients (1 %) underwent pericardiocentesis. 8 (4 %) patients developed a stroke. No wound complications were detected. In the long-term period, 31 patients died. The causes of mortality were the following: cardiovascular diseases – 13 patients, malignant neoplasms – 5 patients, gastrointestinal diseases – 2, urinary system disease – 1 patient, COVID-19 – 1 patient, unknown cause – 9 patients. Thus, the five-year survival rate after the surgery was 63 %, respectively. During the follow-up period, 2 patients (2.9 %) underwent repeated intervention on AV.

Conclusions. The five-year freedom from re-operation was 97.1 %. The five-year survival rate was 63 % due to the presence of a history of severe concomitant pathology as well as the middle age of patients 70 years.

Keywords

aortic valve replacement / biological prosthesis / elderly patients

References

[1] Volkmar Falk, Helmut Baumgartner, Jeroen J. Bax, Michele De Bonis1, Christian Hamm, Per Johan Holm, et al. Guidelines on the management of valvular heart disease (version 2017): the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2017; 52: 616–664. DOI: 10.1093/ejcts/ezx324

[2] Volkmar Falk, Helmut Baumgartner, Jeroen J. Bax, Michele De Bonis1, Christian Hamm, Per Johan Holm, et al. Guidelines on the management of valvular heart disease (version 2017): the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017; 52: 616–664. DOI: 10.1093/ejcts/ezx324

[3] Vahanian A., Alfieri O., Andreotti F., Antunes M.J., Barón-Esquivias G., Baumgartner H., Borger M.A., Carrel T.P., De Bonis M., Evangelista A., Falk V. Guidelines on the management of valvular heart disease (version 2012). Eur. Heart J. 2012; 33 (19): 2451–2496. DOI: 10.1093/eurheartj/ehs109.

[4] Ivanov V.A., Evseev E.P., Ajdamirov Ya.A., Popov S.O., Ivanova L.N., Nikityuk T.G. Evolyuciya protezirovaniya mitral'nogo klapana. Hirurgiya. ZHurnal im. N.I. Pirogova 2018; 7: 23–26. DOI: 10.17116/hirurgia2018723 (in Russian).

[5] Иванов В.А., Евсеев Е.П., Айдамиров Я.А., Попов С.О., Иванова Л.Н., Никитюк Т.Г. Эволюция протезирования митрального клапана. Хирургия. Журнал им. Н.И. Пирогова 2018; 7: 23–26. DOI: 10.17116/hirurgia2018723

[6] Kuchumov A.G., Makashova A., Vladimirov S., Borodin V., Dokuchaeva A. Fluid–Structure Interaction Aortic Valve Surgery Simulation: A Review. Fluids 2023, 8, 295. DOI: 10.3390/fluids8110295

[7] Orlovskij P.I., Gricenko V.V., YUhnev A.D., Evdokimov S.V., Gavrilenko V.I. Iskusstvennye klapany serdca. Pod redakciej akademika RAMN YU.L. SHevchenko. SPb. 2007; 139–210 (in Russian).

[8] Орловский П.И., Гриценко В.В., Юхнев А.Д., Евдокимов С.В., Гавриленко В.И. Искусственные клапаны сердца. Под редакцией академика РАМН Ю.Л. Шевченко. СПб. 2007; 139–210.

[9] Demidov D.P., Astapov D.A., Bogachev-Prokof'ev A.V., ZHeleznev S.I. Ocenka kachestva zhizni posle protezirovaniya aortal'nogo klapana biologicheskimi protezami u pacientov pozhilogo vozrasta. Patologiya krovoobrashcheniya i kardiohirurgiya 2017; 21 (3): 40–47. DOI: 10.21688/1681-3472-2017-3-40-47 (in Russian).

[10] Демидов Д.П., Астапов Д.А., Богачев-Прокофьев А.В., Железнев С.И. Оценка качества жизни после протезирования аортального клапана биологическими протезами у пациентов пожилого возраста. Патология кровообращения и кардиохирургия 2017; 21 (3): 40–47. DOI: 10.21688/1681-3472-2017-3-40-47

[11] Sokolov V.V., Parhomenko M.V., Kovalyov A.I. i dr. Sravnitel'naya ocenka metodov protezirovaniya aortal'nogo klapana u bol'nyh starshe 70 let s aortal'nym stenozom. ZHurnal im. N.V. Sklifosovskogo Neotlozhnaya medi- cinskaya pomoshch' 2018; 7 (3): 227–233. DOI: 10.23934/2223-9022-2018-7-3-227-233 (in Russian).

[12] Соколов В.В., Пархоменко М.В., Ковалёв А.И. и др. Сравнительная оценка методов протезирования аортального клапана у больных старше 70 лет с аортальным стенозом. Журнал им. Н.В. Склифосовского Неотложная медицинская помощь 2018; 7 (3): 227–233. DOI: 10.23934/2223-9022-2018- 7-3-227-233

[13] Milewski R.K., Habertheuer A., Bavaria J.E., Fuller S., Desai N.D., Szeto WY., Korutla V., Vallabhajosyula P. Selection of prosthetic aortic valve and root replacement in patients younger than age 30 years. J Thorac Cardiovasc Surg. 2019; 157 (2): 714–725. DOI: 10.1016/j.jtcvs.2018.06.102. Epub 2018 Nov 14. PMID: 30669231 (in Russian).

[14] Milewski R.K., Habertheuer A., Bavaria J.E., Fuller S., Desai N.D., Szeto WY., Korutla V., Vallabhajosyula P. Selection of prosthetic aortic valve and root replacement in patients younger than age 30 years. J Thorac Cardiovasc Surg. 2019; 157 (2): 714–725. DOI: 10.1016/j.jtcvs.2018.06.102. Epub 2018 Nov 14. PMID: 30669231.

[15] Schnittman S.R., Adams D.H., Itagaki S., Toyoda N., Egorova N.N., Chikwe J. Bioprosthetic aortic valve replacement: Revisiting prosthesis choice in patients younger than 50 years old. J Thorac Cardiovasc Surg. 2018; 155 (2): 539–547.e9. DOI: 10.1016/j.jtcvs.2017.08.121. Epub 2017 Sep 13. PMID: 29110948.

[16] Lund O., Bland M. Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement. J Thorac Cardiovasc Surg. 2006; 132 (1): 20–6. DOI: 10.1016/j.jtcvs.2006.01.043. PMID: 16798297.

[17] Johnston D.R., Soltesz E.G., Vakil N., Rajeswaran J., Roselli E.E., Sabik J.F. et al. Long-term durability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac Surg. 2015; 99 (4): 1239–47. DOI: 10.1016/j. athoracsur.2014.10.070.

[18] Bourguignon T., Bouquiaux-Stablo A.-L., Candolfi P., Mirza A., Loardi C., May M.-A. et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg. 2015; 99 (3): 831–7. DOI: 10.1016/j.athoracsur.2014.09.030

[19] Ruel M., Kulik A., Lam B., Rubens F., Hendry P., Masters R. et al. Longterm outcomes of valve replacement with modern prostheses in young adults. Eur J Cardiothorac Surg. 2005; 27 (3): 425–33. DOI: 10.1016/j. ejcts.2004.12.002.

[20] Enginoev S.T., Kondrat'ev D.A., Caroev B.S., Magomedov G.M., Rashidova T.K., Abdurahmanov A.A., Abdulmedzhidova U.K., Zen'kov A.A., CHernov I.I., Tarasov D.G. Srednesrochnye rezul'taty protezirovaniya aortal'nogo klapana biologicheskim protezom: odnocentrovoe retrospektivnoe issledovanie. Klinicheskaya i eksperimental'naya hirurgiya. ZHurnal imeni akademika B.V. Petrovskogo 2022; 10 (3): 28–37. DOI: 10.33029/2308-1198-2022-10-3-28-37 (in Russian).

[21] Энгиноев С.Т., Кондратьев Д.А., Цароев Б.С., Магомедов Г.М., Рашидова Т.К., Абдурахманов А.А., Абдулмеджидова У.К., Зеньков А.А., Чернов И.И., Тарасов Д.Г. Среднесрочные результаты протезирования аортального клапана биологическим протезом: одноцентровое ретроспективное исследование. Клиническая и экспериментальная хирургия. Журнал имени академика Б.В. Петровского 2022; 10 (3): 28–37. DOI: 10.33029/2308-1198-2022-10-3-28-37

[22] Ahmed K.A., Ahmed J., Samant A.et al. (August 24, 2023) The Longest Known Survival of a Patient With Bioprosthetic Aortic Valve Replacement: A 42-Year Follow-Up. Cureus 15 (8): e44069. DOI: 10.7759/cureus.44069

[23] Reardon M.J., Van Mieghem N.M., Popma J.J., Kleiman N.S., Søndergaard L., Mumtaz M., Adams D.H., Deeb G.M., Maini B., Gada H., Chetcuti S., Gleason T., Heiser J., Lange R., Merhi W., Oh J.K., Olsen P.S., Piazza N., Williams M., Windecker S., Yakubov S.J., Grube E., Makkar R., Lee J.S., Conte J., Vang E., Nguyen H., Chang Y., Mugglin A.S., Serruys P.W., Kappetein A.P. SURTAVI Investigators. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2017; 376 (14): 1321–1331. DOI: 10.1056/NEJMoa1700456. Epub 2017 Mar 17. PMID: 28304219.

[24] Baumgartner H., Falk V., Bax J.J., De Bonis M., Hamm C., Holm P.J., Iung B., Lancellotti P., Lansac E., Rodriguez Muñoz D., Rosenhek R., Sjögren J., Tornos Mas P., Vahanian A., Walther T., Wendler O., Windecker S., Zamorano J.L. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017; 38 (36): 2739–2791. DOI: 10.1093/eurheartj/ ehx391. PMID: 28886619.

[25] Van Mieghem N.M., El Faquir N., Rahhab Z., Rodríguez-Olivares R., Wilschut J., Ouhlous M., Galema T.W., Geleijnse M.L., Kappetein A.P., Schipper M.E., de Jaegere P.P. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015; 8 (5): 718–24. DOI: 10.1016/j.jcin.2015. 01.020. PMID: 25946445.

[26] Van Mieghem N.M., El Faquir N., Rahhab Z., Rodríguez-Olivares R., Wilschut J., Ouhlous M., Galema T.W., Geleijnse M.L., Kappetein A.P., Schipper M.E., de Jaegere P.P. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2015; 8 (5): 718–24. DOI: 10.1016/j.jcin.2015.01.020. PMID: 25946445.

[27] Siontis G.C., Jüni P., Pilgrim T., Stortecky S., Büllesfeld L., Meier B., Wenaweser P., Windecker S. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014; 64 (2): 129–40. DOI: 10.1016/j.jacc.2014.04.033. PMID: 25011716.

[28] Yin W.H., Lee Y.T., Tsao T.P., Wei J. Delayed Coronary Obstruction after Transcatheter Aortic Valve Replacement – An Uncommon But Serious Complication. Acta Cardiol Sin. 2020; 36 (5): 409–415. DOI: 10.6515/ ACS.202009_36 (5).20200516A. PMID: 32952350; PMCID: PMC7490610.

[29] Yin W.H., Lee Y.T., Tsao T.P., Wei J. Delayed Coronary Obstruction after Transcatheter Aortic Valve Replacement – An Uncommon But Serious Complication. Acta Cardiol Sin. 2020; 36 (5): 409–415. DOI: 10.6515/ACS. 202009_36 (5).20200516A. PMID: 32952350; PMCID: PMC7490610.

[30] Mach M., Okutucu S., Kerbel T., Arjomand A., Fatihoglu S.G., Werner P., Simon P., Andreas M. Vascular Complications in TAVR: Incidence, Clinical Impact, and Management. J Clin Med. 2021; 10 (21): 5046. DOI: 10.3390/jcm 10215046. PMID: 34768565; PMCID: PMC8584339.

[31] UK TAVI Trial Investigators; Toff W.D., Hildick-Smith D., Kovac J., Mullen MJм Wendler O., Mansouri A., Rombach I., Abrams K.R., Conroy S.P., Flather M.D., Gray A.M., MacCarthy P., Monaghan M.J., Prendergast B., Ray S., Young C.P., Crossman D.C., Cleland J.G.F., de Belder M.A., Ludman P.F., Jones S., Densem C.G., Tsui S., Kuduvalli M., Mills J.D., Banning A.P., Sayeed R., Hasan R., Fraser D.G.W., Trivedi U., Davies S.W., Duncan A., Curzen N., Ohri S.K., Malkin C.J., Kaul P., Muir D.F., Owens W.A., Uren N.G., Pessotto R., Kennon S., Awad W.I., Khogali S.S., Matuszewski M., Edwards R.J., Ramesh B.C., Dalby M., Raja S.G., Mariscalco G., Lloyd C., Cox I.D., Redwood S.R., Gunning M.G., Ridley P.D. Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial. JAMA. 2022; 327 (19): 1875–1887. DOI: 10.1001/jama.2022.5776. PMID: 35579641; PMCID: PMC9115619.

[32] Madhavan M., Kodali S., Thourani V. et al. Outcomes of SAPIEN 3 Transcatheter Aortic Valve Replacement Compared With Surgical Valve Replacement in Intermediate-Risk Patients. J Am Coll Cardiol. 2023; 82 (2): 109–123. DOI: 10.1016/j.jacc.2023.04.049

[33] Chakos A., Wilson-Smith A., Arora S., Nguyen T.C., Dhoble A., Tarantini G., Thielmann M., Vavalle J.P., Wendt D., Yan T.D., Tian D.H. Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 5-year survival and beyond. Ann Cardiothorac Surg. 2017; 6 (5): 432–443. DOI: 10.21037/acs. 2017.09.10. PMID: 29062738; PMCID: PMC5639224.

[34] Chakos A., Wilson-Smith A., Arora S., Nguyen T.C., Dhoble A., Tarantini G., Thielmann M., Vavalle J.P., Wendt D., Yan T.D., Tian D.H. Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 5-year survival and beyond. Ann Cardiothorac Surg. 2017; 6 (5): 432–443. DOI: 10.21037/acs.2017.09.10. PMID: 29062738; PMCID: PMC5639224.

[35] Bakr Ali M.K., Abdelaal M.M., Elfeky W.M., Abdou Ettish A.A. Mini-Sternotomy Versus Conventional Sternotomy In Aortic Valve Replacement Surgery; A Comparative Study. J Pak Med Assoc. 2023; 73 (Suppl 4) (4): S56–S60. DOI: 10.47391/JPMA.EGY-S4-13. PMID: 37482831.

[36] McGale P., Darby S.C., Hall P., Adolfsson J., Bengtsson N.O., Bennet A.M., Fornander T., Gigante B., Jensen M.B., Peto R., Rahimi K., Taylor C.W., Ewertz M. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol. 2011; 100 (2): 167–75. DOI: 10.1016/j.radonc.2011.06.016. PMID: 21752480.

Funding

Министерство науки и высшего образования Российской ФедерацииMinistry of Science and Higher Education of the Russian Federation(FSNM%2023%0003)

RIGHTS & PERMISSIONS

Eco-Vector